The role of carcinoembryonic antigen (CEA), gamma glutamyl transpeptidase (gamma GT), phosphohexose isomerase (PHI), pseudouridine (PSD) and acute phase reactant proteins (C-reactive protein (C-RP], alpha 1-acid glycoprotein (alpha 1-AGP) and alpha 1-antichymotrypsin (alpha 1-ACT) in distinguishing benign from malignant conditions of the digestive tract and their value in assessing the prognosis of gastrointestinal neoplasms was evaluated. For each marker it has been possible to produce a simple scoring index derived from the values found in the control population. This work suggests that pre-operative levels of certain cancer markers may be useful in tumor detection and may also give prognostic information additional to pathological staging.

Acute-Phase Proteins↗

PubMedDate not supplied

Biochemical markers in gastrointestinal malignancies.

The authors review the role of tumor markers in distinguishing benign from malignant conditions of the digestive tract. They also discuss the value of cancer markers to stratify patients in terms of their survival probability, to detect recurrence and to monitor treatment.

Acute-Phase Proteins↗

PubMedDate not supplied

[Gastric secretion in duodenal ulcer].

Explore the source record for details and available documents.

Duodenal Ulcer↗

PubMedDate not supplied

Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.

In 39 patients with advanced colorectal cancer and no previous chemotherapy, treatment with chlorozotocin was associated with a 5% objective response rate and a median survival of 19 weeks. All of the responses occurred in patients with rectal tumors. Mild gastrointestinal symptoms affected 64% of the patients after treatment, but bone marrow suppression was not evident. Chlorozotocin is not effective against colorectal cancer when used as a single agent given as an iv bolus at doses of 120 mg/m2 (30 patients) and 150 mg/m2 (nine patients). However, further studies using a higher dose might be worthwhile.

Adenocarcinoma↗